ブログ

January 2026 deal activity leaned heavily toward bispecific, trispecific, and ADC assets, particularly in oncology and immunology, alongside steady investment in AI-enabled target discovery and antibody engineering platforms. Several of the month’s largest transactions focused on late preclinical and early clinical programs, pointing to continued pharma interest in differentiated antibody modalities with well-defined mechanisms as the year gets underway.

This article examines HEK293 and CHO across biological characteristics, productivity, glycosylation, product integrity, and application-specific strategy, integrating findings from recent comparative studies.

ADCs to watch in 2026. Clinical Trials, Primary Endpoints.

PepTalk 2026 highlights and event recap. Biotech antibody conference!

Bispecific antibodies (bsAbs) represent a rapidly advancing class of therapeutic biologics engineered to simultaneously bind two distinct antigens or epitopes. Their dual-targeting capability enables novel mechanisms of action, including redirected cytotoxicity, receptor clustering, and enhanced specificity, which are being exploited across oncology, immunology, and infectious disease applications.

Artificial intelligence has greatly improved therapeutic antibody development, not only in discovery and affinity maturation, but increasingly in assessing developability. Developability screening typically relies on resource-intensive workflows, which could delay key decisions about candidate selection until late in the pipeline.

Antibody affinity is a core metric in immunology and biopharmaceutical science. It refers to the strength of the interaction between a single antigen epitope and the paratope (binding site) of an antibody. In the case of VHH antibodies, also called single-domain antibodies or nanobodies, this interaction occurs through the unique, compact paratope located on their heavy-chain-only variable domain.

A roundup of the biggest antibody biotech and pharma deals in December 2025.

The antibody therapeutics landscape continues to evolve rapidly, with 2026 marking notable progress in clinical approvals, pipeline expansions, and novel engineering strategies. This year’s developments reflect the industry’s growing focus on bispecific antibodies, antibody-drug conjugates (ADCs), and next-generation immune-modulating biologics.

Antibody discovery and development remain strategic priorities for major pharmaceutical companies, as evidenced by the significant deal activity in 2025. While the broader biotech sector faced macroeconomic headwinds, antibody-based therapeutics, particularly bispecific antibodies, antibody-drug conjugates (ADCs), and Fc-fusion constructs, continued to attract substantial investment.

VHH antibodies are single-domain antibody fragments derived from the unique heavy-chain-only antibodies (HCAbs) of camelids, including alpacas, llamas, and camels.

As of the end of 2025, 21 ADCs have been approved globally, with four new approvals added in 2025 alone. Antibody-drug conjugates (ADCs) are a class of targeted biotherapeutics that combine the specificity of monoclonal antibodies with the cytotoxic potency of small molecule drugs.